Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

J. Sandborn, William; Gasink, Christopher; Gao, Long-Long; A. BLANK, MARION; Johanns, Jewel; A. Guzzo, Cynthia; E. Sands, Bruce; B. Hanauer, Stephen; R. Targan, Stephan; J. Rutgeerts, Paul; K. Ghosh, Subrata; J.S. de Villiers, Willem; Panaccione, Remo; R. Greenberg, Gordon; Schreiber, Stefan; Lichtiger, Simon; G. Feagan, Brian

doi:10.1056/nejmoa1203572

Public

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

Shared by NobleBlocks on Oct 18, 2012 • 12:00 AM UTC

Authors:

William J. Sandborn

Christopher Gasink

Long-Long Gao

Abstract

BACKGROUND: In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown. METHODS: We evaluated ustekinumab in adults with moderate-to-severe Crohn's disease that was resistant to anti-tumor necrosis factor (TNF) tre...

Subject

Medicine

Ustekinumab

Crohn's disease

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!